Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for Alzheimer’s. Philippa Salter, managing neurology analyst at GlobalData ...

Meanwhile, it could also help offset concerns that the rate of ARIA-E and ARIA-H are a little higher with Kisunla than with Leqembi. The company said it plans to submit the TRAILBLAZER-ALZ 6 data ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.